Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine
Wednesday, June 12, 2013 - 18:30
in Health & Medicine
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer.